Obese men and women given 3.75 mg of controlled-release phentermine plus 23 mg of controlled-release topiramate (Topamax)—the trade name of this drug combination is Qnexa—lost an average of 5.1% of body weight after one-year compared to an average weight loss of 1.6% for those given a placebo according to a study from the researchers at the University of Alabama at Birmingham.

Obese men and women given 15 mg of controlled-release phentermine plus 92 mg of controlled-release topiramate (Topamax)—the trade name of this drug combination is Qnexa— lost an average of 10.9% of body weight after one-year compared to an average weight loss of 1.6% for those given a placebo according to a study from the researchers at the University of Alabama at Birmingham.

The most common side effects in people given controlled-release phentermine plus controlled-release topiramate (Topamax)—the trade name of this drug combination is Qnexa—according to a study from the researchers at the University of Alabama at Birmingham, were:

• paresthesia (tingling or pricking of a person’s skin, a feeling of “pins and needles”
• dry mouth
• constipation
• altered taste (dysgeusia), and
• insomnia.

“Depression-related adverse events (excluding sleep disorders)” occurred in 7.3 percent of patients given 15 mg of phentermine plus 92 mg of Topamax (topiramate) versus 3.8 percent in those given 7.5 mg of phentermine plus 46 mg of Topamax (topiramate) versus 3.8 percent in those given a placeboaccording to a new study from Duke University in Durham, North Carolina, USA.

It took an average of approximately one-month for these symptoms to occur.

“Anxiety-related adverse events (including irritability)” occurred in 7.7 percent of patients given 15 mg of phentermine plus 92 mg of Topamax (topiramate) versus 4.9 percent in those given 7.5 mg of phentermine plus 46 mg of Topamax (topiramate) versus 2.8 percent in those given a placeboaccording to a new study from Duke University in Durham, North Carolina, USA.

It took an average of approximately one-month for these symptoms to occur.

“Anxiety-related adverse events (including irritability)” occurred in 3.5 percent of patients given 15 mg of phentermine plus 92 mg of Topamax (topiramate) versus 2 percent in those given 7.5 mg of phentermine plus 46 mg of Topamax (topiramate) versus 0.7 percent in those given a placeboaccording to a new study from Duke University in Durham, North Carolina, USA.

Kidney stones were 5 times more common in people given 15 mg of phentermine plus 92 mg of Topamax (topiramate) than those given either a placebo or 7.5 mg of phentermine plus 46 mg of Topamax (topiramate) according to a new study from Duke University in Durham, North Carolina, USA.

People given 7.5 mg of phentermine plus 46 mg of Topamax (topiramate) lost an average of 17.8 pounds in one year versus a weight loss of 3.1 pounds in those given a placebo according to a new study from Duke University in Durham, North Carolina, USA.

The weight loss represented 7.8 percent of body weight for the drug group versus 1.2 percent for the placebo group.

People given 15 mg of phentermine plus 92 mg of Topamax (topiramate) lost an average of 22.4 pounds in one year versus a weight loss of 3.1 pounds in those given a placebo according to a new study from Duke University in Durham, North Carolina, USA.

The weight loss represented 9.8 percent of body weight for the drug group versus 1.2 percent for the placebo group.

Note: This is the average weight loss for people regardless of whether they completed the one-year study or if they dropped out early.

The most common adverse events in people given phentermine plus Topamax (topiramate) were as follows.

The percentages shown are for those give 15 mg of phentermine plus 92 mg of Topamax (topiramate) versus those give 7.5 mg of phentermine plus 46 mg of Topamax (topiramate) versus placebo.

• Paraesthesia (tingling, pricking, or numbness of the skin) in 21% vs 14% vs 2%
• Dry Mouth in 21% vs 13% vs 2%
• Constipation in 17% vs 6% vs 5%
• Insomnia in 10% vs 7% vs 3%
• Dizziness in 10% vs 7% vs 3%
• Dysgeusia (altered taste) in 10% vs 7% vs 1%

In this video clip, which aired on ABC’s Nightline on November 11th, 2009, they are talking about three “new” diet drugs.

The woman in the video, who was given Qnexa (phentermine plus Topamax), lost 55 lbs, dropping from 232 lbs to 177 lbs.

The man, who was given the same drug, lost 73 lbs, dropping from 343 lbs to 270 lbs.

Note: These are probably the two people who have lost the most weight on these drugs.

The average weight loss with these drugs is much less than this.

Among patients given a full dose of Qnexa (15 mg Phentermine plus 92 mg Topamax), 2.1% and 2.6% dropped out of two study due to cognitive side effects such as “disturbance in attention” or “forgetfulness” compared to 0.3% and 0.8% of those given the placebo reports TheStreet.com.

This had not been previously disclosed by Vivus, the company developing this drug.

Overweight and obese patients given the highest dose of Qnexa, containing 15 mg of phentermine plus 92 mg of Topamax (topiramate), lost an average weight loss of roughly 24 pounds versus 5 pounds with placebo after one year, or 10.4 percent of body weight versus 1.8 percent with placebo according to a press release from press release from Vivus, Inc, the company developing the drug.

Overweight and obese patients given the Mid-dose of Qnexa, containing 7.5 mg of phentermine plus 46 mg of Topamax (topiramate), lost an average weight loss of roughly 19 pounds versus 5 pounds with placebo after one year, or 8.4 percent of body weight versus 1.8 percent with placebo according to a press release from press release from Vivus, Inc, the company developing the drug.

Morbidly obese patients given the highest dose of Qnexa, containing 15 mg of phentermine plus 92 mg of Topamax (topiramate), lost an average weight loss of roughly 28 pounds versus 6 pounds with placebo after one year, or 11 percent of body weight versus 1.6 percent with placebo according to a press release from press release from Vivus, Inc, the company developing the drug.

Morbidly obese patients given the lowest dose of Qnexa, containing 3.75 mg of phentermine plus 23 mg of Topamax (topiramate), lost an average weight loss of 18 pounds versus 6 pounds with placebo after one year, or 5.1 percent of body weight versus 1.6 percent with placebo according to a press release from press release from Vivus, Inc, the company developing the drug.

The most common side effects reported by overweight and obese patients given the Qnexa (phentermine plus controlled-release Topamax (topiramate)) were dry mouth, tingling, constipation, altered taste and insomnia according to a press release from press release from Vivus, Inc, the company developing the drug.

The most common side effects reported by patients given a half-dose of Qnexa (7.5 mg of phentermine plus 46 mg of Topamax) or a full-dose of Qnexa (15 mg of phentermine plus 92 mg of Topamax) were:

• 15-20% reported paresthesia (a feeling of “pins and needles” on the skin) versus 3% in the placebo group
• 12-18% reported dry mouth versus 0% in the placebo group
• 8-15% reported altered taste versus 0% in the placebo group
• 6-11% reported constipation versus 6 percent in the placebo group
• 0.9-1.9% reported depression and altered mood versus 1.8 percent in the placebo group

A half dose of Qnexa, which is 7.5 mg of phentermine plus 46 mg of Topamax (topiramate), caused an average weight loss of 18.2 pounds versus 3.3 pounds with placebo, or 8.5 percent versus 1.7 percent during a six month study according to a press release from press release from Vivus, Inc, the company developing the drug.

A full dose of Qnexa, which is 15 mg of phentermine plus 92 mg of Topamax (topiramate), caused an average weight loss of 19.8 pounds versus 3.3 pounds with placebo, or 9.2 percent versus 1.7 percent during a six month study according to a press release from press release from Vivus, Inc, the company developing the drug.

A low dose of Qnexa, which is 7.5 mg of phentermine plus 46 mg of Topamax (topiramate), caused a weight loss of at least 5 percent in 62 percent of patients versus 15 percent given the placebo during a six month study according to a press release from press release from Vivus, Inc, the company developing the drug.

A full dose of Qnexa, which is 15 mg of phentermine plus 92 mg of Topamax (topiramate), caused a weight loss of at least 5 percent in 66 percent of patients versus 15 percent given the placebo during a six month study according to a press release from press release from Vivus, Inc, the company developing the drug.

Here is an update to a previous story of a 43-year-old man who had lost 44 pounds in three months on the experimental drug Qnexa, which is simply a combination of phentermine and Topamax (topriamate).

As of now, which is approximately 4 months, he has lost 50 pounds.

Here is a short story of a 43-year-old man named Ray who lost 44 pounds in three months who is part of a trial involving phentermine plus Topamax (topiramate).

A drug called Qnexa, which is really just a combination of phentermine and Topamax (topiramate), caused half of the patients to lose an average of 25.1 pounds after six months compared to 4.8 pounds for those given a placebo.